First-line treatment strategies for BRAF-V600E mutated non-small cell lung cancer: lessons from real-world data and ongoing uncertainties
Current evidence supports both BRAF/MEK inhibitor combinations and immune‑checkpoint inhibitor‑based regimens as reasonable first‑line options for patients with BRAF‑V600E mutated NSCLC, each with distinct advantages and limitations.
Optimal first‑line therapy for BRAF‑V600E mutated NSCLC remains undefined; the existing evidence indicates that both BRAF/MEK inhibitor combinations and ICI‑based regimens can be considered reasonable options, guiding clinicians in personalized treatment decision‑making.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT